# Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease

> **NCT01696396** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 254 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** Abrilumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01696396
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-04
- **Primary completion:** 2014-12-26
- **Final completion:** 2018-04-10
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2019-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696396, "Abrilumab (AMG 181) in Adults With Moderate to Severe Crohn's Disease". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01696396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*